1175 LONG TERM OUTCOME OF PATIENTS FOLLOWED FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC) PRESENTING WITH POSITIVE NMP22 AND NEGATIVE CYTOLOGY AND CYSTOSCOPY

Abstract

You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20101175 LONG TERM OUTCOME OF PATIENTS FOLLOWED FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC) PRESENTING WITH POSITIVE NMP22 AND NEGATIVE CYTOLOGY AND CYSTOSCOPY Vincenzo Serretta, Fabio Scuto, Antonina Ruggirello, Dario Passalacqua, Rosalinda Allegro, and Darvinio Melloni Vincenzo SerrettaVincenzo Serretta More articles by this author , Fabio ScutoFabio Scuto More articles by this author , Antonina RuggirelloAntonina Ruggirello More articles by this author , Dario PassalacquaDario Passalacqua More articles by this author , Rosalinda AllegroRosalinda Allegro More articles by this author , and Darvinio MelloniDarvinio Melloni More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.675AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES NMP22 has been introduced in diagnosis and follow-up of bladder cancer. Although several causes of false positive results have been identified, the clinical value of positive NMP22 is often doubtful. We present the long term outcome of patients in follow-up for previous NMI bladder cancer presenting with NMP elevated values in spite of negative cytology, cystoscopy and urography. METHODS A urine collection kit, containing urine stabilizer and a test kit using MAb302-18 and MAb302-22, developed by Matritech Inc. was used. Urine samples were obtained in all patients after a single spontaneous void and frozen at -20°C immediately after collection. A cut-off value of 10 units/ml was adopted. A positive NMP22 was obtained in 95 patients in follow-up for Ta-T1 G1-3 bladder cancer. In 50 patients (53%) intravesical chemotherapy was given and urine was obtained after an interval of 7-30 days. Cytology, cystoscopy and urography were negative. No other urological pathology was evident except for asymptomatic BPH. Since 1996 all patients were maintained into a close follow-up with urinary cytology and cystoscopy every 3 months for the first 2 years and 6-monthly thereafter. All suspicious lesions at cystoscopy were biopsied. A bladder mapping was performed in the case of negative cystoscopy and positive or doubt cytology. RESULTS Median follow-up was 51 months (range: 2-174). Five patients only (5%) were lost at follow-up before 2 years and 3 patients died. The median interval between the last recurrence and NMP22 determination was 39 months. Thirty-seven (39%) patients recurred at a mean interval of 13 months from NMP22 test. No significant difference was evident in NMP22 levels between recurring and recurrence-free patients (p=0.26). The results were not influenced by intravesical chemotherapy (p=0.87). No clinically relevant difference emerged in recurrence-free survival according to NMP22 values higher or lower than 10 U/ml (38 vs 31 months) although statistically significant. CONCLUSIONS Positive urine NMP22 in patients in follow-up for previous NMI-BC is not associated with a higher risk of recurrence when accompanied by negative cytology and cystoscopy. Palermo, Italy© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e455 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Vincenzo Serretta More articles by this author Fabio Scuto More articles by this author Antonina Ruggirello More articles by this author Dario Passalacqua More articles by this author Rosalinda Allegro More articles by this author Darvinio Melloni More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...